Fwd: Lancet Editorial: Safety of Swine Flu vaccine a Concern. (fwded)
Venugopalan K M
From: Jagannath Chatterjee <jagc...@yahoo.com>
Date: Sun, Aug 16, 2009 at 9:24 AM
Subject: [IHRO] Lancet Editorial: Safety of Swine Flu vaccine a Concern.
Dear Friends,
Activists are always accused of being unscientific. But we do go
through medical journals and cross check what we post. During my 24
years of campaign against vaccines no one has ever been able to accuse
me of wrong information.
I was reserving this Lancet editorial for such kind of accusations
post my mails against the swine flu vaccine. Here is the mighty Lancet
on the Swine Flu Vaccination. Will my dear friends refute this too?
I have placed so much of scientific evidence on these lists. Results
of my years of tracking various reputed medical journals for peer
reviewed articles. Why do my distractors remain silent in such
moments? Why don't they act on such information and approach the
government to stop the vaccination program that is harming the
children of the nation?
Dialogue is a two way street my brothers. You just can't have it only
your own way. Particularly when small children are the targets.
Regards,
Jagannath.
www.thelancet..com Vol 374 August 1, 2009
Editorial
Last week, Australia and the USA announced that they
would begin trials of an H1N1 vaccine. Vaccination against
H1N1 will be an important development in controlling
the impact of the pandemic. However, several thorny
issues exist around vaccine manufacture and approval.
All countries will require the vaccine but current global
manufacturing capacity will not be able to meet this
demand. Additionally, experts think that individuals might
need two doses of the vaccine instead of one, reducing
capacity further. Vaccine manufacturers are also struggling
to produce good vaccine yields with the H1N1 seed virus.
One way to ease these supply problems is the use
of adjuvants in a vaccine. On July 7, WHO’s Strategic
Advisory Group of Experts on Immunization
recommended that vaccine formulated with oil-inwater
adjuvants and live-attenuated influenza vaccines
should be promoted to help increase the global supply
of a vaccine and because they are better at protecting
against strain variations. Yet there are signs that the USA
might not follow this recommendation. “Adjuvant use
would be contingent upon showing that it was needed
or clearly beneficial”, Jesse Goodman, acting chief
scientist and deputy commissioner of the Food and Drug
Administration told a press briefi ng on July 17. The USA
must support the use of dose-sparing strategies to avoid
depletion of an already short vaccine supply.
As well as availability, safety of an H1N1 vaccine is a
concern. Many national regulatory agencies have setup
fast-track approval processes for the H1N1 vaccine,
which means that a vaccine might be licensed without
the usual safety and efficacy data requirements. Vaccine
safety will therefore have to be monitored through postmarketing
surveillance. But some fear a repeat of the
1976 H1N1 outbreak in the USA, where mass vaccination
was associated with complications, which stopped the
campaign and led to the withdrawal of the vaccine.
Countries need to assess carefully the risks and
benefi ts of rapid approval of an H1N1 vaccine, especially
since the disease has so far been mild with most patients
making a full recovery. They must also ensure that they
have strong post-marketing surveillance in place before
rolling out a vaccine. ¡ The Lancet.
Lancet 2009 HIN1 vaccination editorial - August.pdf
All it takes is just one vaccine to forever change your life. - Dawn,
mother of vaccine damaged child.
You cannot build anything on the foundations of caste. You cannot
build up a nation, you cannot build up a morality. Anything that you
will build on the foundations of caste will crack and will never be a
whole.
-AMBEDKAR